Vitrolife

Board/Management Information • Feb 21, 2025

The Vitrolife Group appoints Ermanno Sironi as Chief Operating Officer

The Vitrolife Group is strengthening the executive management team with the introduction of the role of Chief Operating Officer (COO), appointing Ermanno Sironi to the position effective immediately.

The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as the IT organisation. The appointment supports continued execution of the corporate strategy to drive operational excellence, implementing a scalable operating model, optimising processes to realise synergies and leveraging digitalisation to increase productivity.

Ermanno Sironi is a tenured MedTech executive with over 30 years' experience working in Operations, Finance and Business Development in global companies. Over the past year, he has served as a strategic advisor on operational excellence and business transformation to the Vitrolife Group's executive management team.

"We are delighted that Ermanno has accepted the role of COO. His deep industry experience and strong track record of leading operational transformations will support the company to deliver on this key strategic pillar." Bronwyn Brophy O'Connor, CEO of the Vitrolife Group.

Gothenburg, 21 February 2025 VITROLIFE AB (publ) Bronwyn Brophy O'Connor, CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 21-02-2025 13:00 CET.

Contact:

Amelie Wilson, Investor Relations, phone +46 (0)70 822 80 12

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.